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Over the past three decades a body of translational evidence has implicated dietary deﬁciency in long-
chain omega-3 (LCn-3) fatty acids, including eicosapenaenoic acid (EPA) and docosahexaenoic acid
(DHA), in the pathophysiology and etiology of major depressive disorder (MDD). Cross-national and
cross-sectional data suggest that greater habitual intake of preformed EPA þ DHA is associated with
reduced risk for developing depressive symptoms and syndromal MDD. Erythrocyte EPA and DHA
composition is highly correlated with habitual ﬁsh or ﬁsh oil intake, and case-control studies have
consistently observed lower erythrocyte EPA and/or DHA levels in patients with MDD. Low erythrocyte
EPA þ DHA composition may also be associated with increased risk for suicide and cardiovascular dis-
ease, two primary causes of excess premature mortality in MDD. While controversial, dietary EPA þ DHA
supplementation may have antidepressant properties and may augment the therapeutic efﬁcacy of
antidepressant medications. Neuroimaging and rodent neurodevelopmental studies further suggest that
low LCn-3 fatty acid intake or biostatus can recapitulate central pathophysiological features associated
with MDD. Prospective ﬁndings suggest that low LCn-3 fatty acid biostatus increases risk for depressive
symptoms in part by augmenting pro-inﬂammatory responsivity. When taken collectively, these trans-
lational ﬁndings provide a strong empirical foundation in support of dietary LCn-3 fatty acid deﬁciency as
a modiﬁable risk factor for MDD. This review provides an overview of this translational evidence and
then discusses future directions including strategies to translate this evidence into routine clinical
screening and treatment algorithms.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
2. LCn-3 fatty acid biosynthesis and biostatus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
3. Relevance to depression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
3.1. Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
3.2. LCn-3 fatty acid biosynthesis and biostatus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
3.3. LCn-3 fatty acid supplementation studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
4. Neuroimaging studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
5. Rodent studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
6. Future directions e clinical implementation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
7. Screening for LCn-3 fatty acid deﬁciency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
8. Treating LCn-3 fatty acid deﬁciency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
9. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102r Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Diagram illustrating the biosynthetic pathway of omega-3 fatty acids. The
biosynthesis of docosahexaenoic acid (DHA, 22:6n-3) from dietary a-linolenic acid
(18:3n-3) requires a series of microsomal elongation (ELOVL5) and delta-5 (FADS1) and
delta-6 desaturase (FADS2) mediated reactions. The ﬁnal synthesis of DHA is catalyzed
by b-oxidation within peroxisomes. Metabolism of DHA yields inﬂammation-resolving
docosanoids. Preformed DHA and EPA can also be obtained directly from the diet.
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Major depressive disorder (MDD) is a leading cause of disability
globally. In the United States (U.S.) severe forms of MDD are esti-
mated to affect between 2 and 7% of the population and up to
16e20% suffer from milder forms [106]. The initial onset of MDD
frequently occurs during adolescence and young adulthood [105],
and is ~2-fold more prevalent in females after puberty [104]. Out-
comes data indicate that MDD is associated with excess premature
mortality primarily attributable to suicide and cardiovascular-
related disorders [9,152]. Bipolar disorder is also associated with
recurrent episodes of depression, and prodromal MDD is a risk
factor for mania in at-risk youth [15,55,91]. The ﬁrst-line treatment
for MDD in adolescents and adults is typically a selective serotonin
reuptake inhibitor (SSRI). However, approximately 30e40% of
adolescent MDD patients exhibit residual symptoms following
standard SSRI treatment [58,103], and SSRI treatment may precip-
itate suicidality and mania in at-risk youth [27,81,124,171]. These
and other data highlight an urgent need to identify modiﬁable risk
and resilience mechanisms associated with the etiology of MDD to
inform improvements in treatment and ultimately prevention
strategies.
While aggressive efforts have been devoted to the identiﬁcation
of genetic risk factors associated with psychiatric disorders
including MDD, it has become apparent that both genetic and
environmental factors confer vulnerability [56,141]. For example, a
meta-analysis of community-based twin studies of MDD yielded a
heritability estimate of .37, indicating that approximately two
thirds of the liability is attributable to environmental factors [177].
Moreover, environmental factors can regulate gene expression
through epigenetic effects (i.e., DNA methylation) independent of
DNA sequence polymorphisms [157,192]. Environmental factors
can also interact with DNA polymorphisms to increase risk for
developing psychiatric disorders [34]. Accordingly, aggressive ef-
forts also need to be devoted to the identiﬁcation of environmental
risk factors, particularly in view of their amenability tomodiﬁcation
and prevention.
Over the last three decades a body of translational evidence has
emerged which suggests that the habitual diet is relevant to the
etiology of MDD. Speciﬁcally, evidence has implicated dietary
deﬁciency in essential long-chain omega-3 (LCn-3) fatty acids,
including eicosapenaenoic acid (EPA) and docosahexaenoic acid
(DHA), in the pathophysiology and etiology of MDD. This is sup-
ported by converging evidence from cross-national and cross-
sectional epidemiological surveys, case-control LCn-3 fatty acid
biostatus studies, prospective observational and LCn-3 fatty acid
intervention studies, rodent neurodevelopmental studies, and
recent neuroimaging ﬁndings. Additionally, accumulating evidence
suggests that LCn-3 fatty acid deﬁciency may increase risk for
suicide and cardiovascular disease, two primary causes of excess
premature mortality in patients withMDD. This review provides an
overview of translational evidence implicating LCn-3 fatty acid
deﬁciency in the pathophysiology and etiology of MDD, and then
discusses future directions including strategies to translate this
evidence into routine clinical screening and treatment algorithms.
2. LCn-3 fatty acid biosynthesis and biostatus
As background, omega-3 (n-3) and omega-6 (n-6) fatty acids are
members of the polyunsaturated fatty acid (PUFA) family. Primary
dietary sources of the short-chain n-3 fatty acid precursor a-lino-
lenic acid (ALA, 18:3n-3) include ﬂaxseed, linseed, canola, soy, and
perilla oils, and primary dietary sources of the short-chain n-6 fatty
acid precursor linoleic acid (18:2n-6) include safﬂower, soy, and
corn oils. These PUFAs are considered ‘essential’ because mammalsare entirely dependent on dietary sources to procure and maintain
adequate concentrations in peripheral and central tissues. The
biosynthesis of long-chain n-3 (LCn-3) fatty acids, including EPA
(20:5n-3) and DHA (22:6n-3), from their short-chain precursors
require a series of common and competitive microsomal desatu-
ration and elongation reactions (Fig. 1) [163]. The rate-limiting
enzymes regulating LC-PUFA biosynthesis include delta-6 desa-
turase (delta6-desaturase, FADS2) and delta-5 desaturase (delta5-
desaturase, FADS1), as well as elongases (e.g., ELOVL5), and the
ﬁnal synthesis of DHA is catalyzed by b-oxidation within peroxi-
somes [185]. FASD1 and FADS2 genes are primarily expressed in the
liver and brain and are co-localized to human chromosome 11q12-
11q13.1 [122]. Desaturase enzymes are regulated by several factors
including gonadal hormones [18,29,38,70,130], insulin [26], as well
as single nucleotide polymorphisms within FADS2 and/or FASD1
genes [115]. Recent evidence further suggests that epigenetic ef-
fects (i.e., DNA methylation) are associated with delta5/6-
desaturase enzyme activity [90] and that PUFA intake can induce
DNA methylation resulting in reduced expression of FADS2 and
ELOVL5 [88,89,148]. Therefore, PUFA homeostasis is ultimately
governed by both environmental (i.e., diet) and genetic factors.
In healthy adult subjects ALA/EPA biosynthesis is extremely
limited and ALA/DHA and EPA/DHA biosynthesis is negligible
[25]. For example, 12-week supplementation with up to 3.6 g/d of
ﬂaxseed oil, a rich source of ALA, resulted in moderate increases in
erythrocyte (red blood cell) EPA but did not signiﬁcantly increase
erythrocyte DHA levels in healthy adult subjects [19]. Similarly, 4-
week supplementation with ﬂaxseed oil resulted in moderate in-
creases in erythrocyte and breast milk EPA but did not signiﬁcantly
increase erythrocyte or breast milk DHA [64]. This limitation in
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linoleic acid (18:2n-6) in the diet [179]. Unlike ﬂaxseed oil, sup-
plementation with ﬁsh oil robustly increases erythrocyte and
breastmilk EPA þ DHA biostatus [12,19,63]. Primary sources of
preformed LCn-3 fatty acids (EPA þ DHA) include fatty cold water
ﬁsh, including salmon, trout, tuna, as well as ﬁsh oil and algal-
derived supplements. Accordingly, cross-national evidence has
found that habitual ﬁsh intake is positively correlated with
breastmilk [24] and blood [97,164] EPA þ DHA composition.
Together, these ﬁndings highlight the limited efﬁciency of hepatic
PUFA biosynthesis in healthy human subjects and suggest that LCn-
3 fatty acid biostatus is highly dependent on the LCn-3 fatty acid
composition of the habitual diet.3. Relevance to depression
3.1. Epidemiology
Cross-national epidemiological surveys have observed a signif-
icant inverse correlation between per capita ﬁsh or seafood con-
sumption (primary dietary sources of preformed EPA þ DHA) and
lifetime prevalence rates of MDD [85,156], postpartum depression
[86], and bipolar spectrum disorders [149]. Several cross-sectional
studies have investigated the relationship between habitual ﬁsh
or ﬁsh oil intake and depression rates in the general population. For
example, a cross-sectional survey of 21,835 adult and elderly sub-
jects fromNorway found that subjects who ingested cod liver oil on
a daily basis (EPA: ~300e600 mg/d; DHA: ~300e600 mg/d) were
30% less likely to have depressive symptoms than non-users after
adjusting for multiple possible confounding factors [161]. A meta-
analyses of thirteen cross-sectional studies found that higher
intake of ﬁsh (as well as fruit, vegetables, and whole grains) was
signiﬁcantly associated with a reduced depression risk [110].
Because the initial onset of MDD frequently occurs during adoles-
cence, it is relevant that lower dietary LCn-3 fatty acid intake in
adolescents is associated with elevated depressive symptoms as
well as cardiovascular risk factors [5,145,150,153,178]. Although
these ﬁndings provide indirect support for an inverse association
between ﬁsh intake frequency and MDD prevalence, numerous
cultural and genetic variables may also contribute to this
association.
It has been estimated that there has been a sharp increase in the
consumption of linoleic acid (18:2n-6), and a reciprocal decline in
a-linolenic acid (18:3n-3) and LCn-3 fatty acids, in the U.S. over the
last century [21]. While it is unclear whether this relative decline in
LCn-3 fatty acids has been associated with a change in the preva-
lence rates of depression in the U.S., a retrospective study found
that shifts away from ﬁsh-based to Western diets in Arctic com-
munities was associated with increased rates of seasonal affective
disorder, depression, suicide, and cardiovascular disease [126].
Moreover, case-control studies ﬁnd that patients with mood dis-
orders aremore likely to consume diets with lower amounts of LCn-
3 fatty acids and ALA compared with healthy controls and/or rec-
ommended intake levels [39,48,54,60,98]. It is also relevant that
MDD is associated with excess premature mortality primarily
attributable to suicide and cardiovascular disease [9,152], and
cross-sectional epidemiological evidence suggests that higher LCn-
3 fatty acid intake may be protective against suicidality [180] and
cardiovascular disease [187]. Together these ﬁndings suggest that
habitual diets containing lower amounts of LCn-3 fatty acids may
increase risk for developing depressive symptoms, suicidality, and
co-morbid cardiovascular disease.3.2. LCn-3 fatty acid biosynthesis and biostatus
Extant evidence from genome-wide association studies does not
support an association between polymorphisms in delta-6 (FASD2)
and delta-5 desaturase (FADS1) genes in the etiology of MDD [117].
A recent genotyping study did not observe an association between
common single-nucleotide polymorphisms in FADS1 or FASD2
genes and depression or suicidality [176]. However, DNA methyl-
ation in the Elovl5 gene was found to be associated with depression
and suicidality [78]. Moreover, FADS1 mRNA expression was
signiﬁcantly lower in the postmortem prefrontal cortex of MDD
patients relative to controls, and there were trends for lower
expression of FADS2 and ELOVL5 [135]. A microarray study similarly
found that FADS1 expressionwas reduced in postmortem prefrontal
cortices of male MDD patients that committed suicide [114]. It is
also notable that antidepressant medications up-regulate the
expression of sterol regulatory element-binding protein (SREBP)
[160] which positively regulates FADS1 and FADS2 transcription
[125]. While these ﬁndings must be viewed as preliminary, they
suggest that the dysregulation in LCn-3 fatty acid homeostasis in
MDD may be mediated in part by epigenetic modiﬁcations of
biosynthetic enzymes.
Several independent cross-sectional studies conducted in
different countries have observed signiﬁcantly lower erythrocyte
membrane or plasma phospholipid EPA þ DHA levels in adult MDD
patients compared with healthy controls. A meta-analysis of 14
cross-sectional fatty acid composition studies found signiﬁcant
deﬁcits in EPA and DHA, but not arachidonic acid (AA), in MDD
patients [118]. Other cross-sectional studies have similarly found
that pediatric and adolescent patients with MDD exhibit erythro-
cyte EPA þ DHA deﬁcits compared with healthy youth [39,138,158].
Some studies [2,39,54], but not others [14,119,133], have observed
an inverse correlation between blood EPA þ DHA levels, or a pos-
itive correlation between the AA/EPA ratio, and depression symp-
tom severity. It is notable that erythrocyte EPA and/or DHA deﬁcits
are not unique to MDD, and have also been observed in patients
with bipolar I disorder [140], anxiety disorders [75], and schizo-
phrenia [182]. While there may be different etiological factors
contributing to lower blood EPA þ DHA levels observed in MDD
patients, dietary ﬁsh oil supplementation, but not ﬂaxseed oil
supplementation [71], is sufﬁcient to robustly increase patient
blood EPA þ DHA levels [138]. In view of evidence that erythrocyte
EPA þ DHA composition is highly correlated with habitual dietary
ﬁsh intake and/or ﬁsh oil supplementation [63,97,164], these data
suggest that dietary EPA þ DHA insufﬁciency represents a modiﬁ-
able risk factor for EPA þ DHA deﬁciency observed in MDD.
Several lines of evidence also suggest that increasing LCn-3 fatty
acid status may reduce risk of suicide, a primary cause of excess
premature mortality in MDD [9,152]. A prospective longitudinal
study found that low baseline plasma DHA composition was a
signiﬁcant predictor of future suicidal attempts in medication-free
MDD patients [174]. In two case-control studies, erythrocyte or
plasma LCn-3 fatty acid composition was found to be signiﬁcantly
reduced in suicidal patients [66,93]. Two controlled trials found
that dietary LCn-3 fatty acid supplementation reduced suicidality in
MDD patients [79,155]. However, prospective cohort studies have
not observed an association between LCn-3 fatty acid intake and
completed suicide in the general population [181]. Therefore, while
extant evidence suggests that increasing LCn-3 fatty acid status in
patients with psychiatric illness may be protective against suici-
dality, additional research is needed to evaluate whether depressed
mood mediates this effect.
Excess premature mortality in patients with MDD is also
attributable to cardiovascular-related diseases [9,152]. Cross-
sectional and prospective longitudinal studies suggest that low
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for cardiometabolic risk factors [61,101,127] and sudden cardiac
arrest [4,82,92,169]. Moreover, LCn-3 fatty acid intake is associated
with methylation of genes regulating immune-inﬂammatory and
lipid homeostasis [13,116], and the low erythrocyte EPA þ DHA
levels observed in patients with MDD are associated with elevated
serum levels of triglycerides and pro-inﬂammatory molecules
including C-reactive protein [16,17]. Additionally, the low erythro-
cyte EPAþ DHA levels observed in patients withMDD are similar to
levels observed in patients suffering acute coronary syndrome [22]
and would be anticipated to increase their risk for sudden cardiac
arrest [82](Fig. 2). While the effects of LCn-3 fatty acid supple-
mentation on cardiovascular events and sudden cardiac arrest in
patients with a history of cardiovascular disease have been equiv-
ocal [109], primary prevention studies in subjects without a history
of cardiovascular disease [186] or subjects at high-risk for cardio-
vascular disease [57] suggest that increasing LCn-3 fatty acid bio-
status may have protective beneﬁts. While there have been no LCn-
3 fatty acid primary prevention studies conducted in patients with
MDD, existing evidence provides a rationale for identifying and
treating LCn-3 fatty acid deﬁciency in patients presenting with
other cardiovascular risk factors.
The primary LCn-3 fatty acid found in mammalian brain gray
matter is DHA, which comprises approximately 15% of total fatty
acid composition [33,45,129]. Although EPA (20:5n-3) crosses the
blood-brain barrier, it is rapidly oxidized and consequently com-
prises <1% of total brain fatty acid composition [36]. In general
human erythrocyte and frontal cortex DHA composition are posi-
tively correlated [33], and non-human primate studies indicate that
DHA recuperation occurs more rapidly in erythrocytes than cortical
gray matter following dietary ﬁsh oil supplementation [45]. Case-
control studies have investigated the fatty acid composition of
postmortem brain tissue fromMDD patients and/or suicide victims.
These studies have observed DHA deﬁcits in the prefrontal cortex or
anterior cingulate of adult patients with MDD [43,128,136], but not
in the prefrontal cortex of adolescent or adult suicide victims
[113,131]. Other postmortem studies have not observed signiﬁcant
DHA deﬁcits in temporal lobe structures including the amygdala inFig. 2. Comparison of the mean erythrocyte ‘omega-3 index’ (EPA þ DHA composition)
in adult patients with acute coronary syndrome (ACS) residing in the U.S. (n ¼ 768)
[22], adult patients with MDD residing in the Chicago area (n ¼ 20) , normative values
from a cohort of subjects residing in the U.S (n ¼ 11,329, http://www.omegaquant.com/
fatty-acids-regularly-measured/), and adults residing in Japan (n ¼ 456) [97]. Proposed
‘risk zones’ for sudden cardiac death derived from prospective longitudinal studies are
indicated [82]. Note that MDD patients exhibit an ‘omega-3 index’ that is similar to
patients with ACS, and places them at ‘high risk’ for sudden cardiac arrest. In view of
evidence implicating both EPA and DHA deﬁciency in the pathophysiology of MDD, it is
proposed that similar ‘risk zones’ be adopted in psychiatric practice to identify patients
requiring corrective supplementation. Controlled intervention studies suggest that
daily EPA þ DHA doses of 1e2 g are sufﬁcient to increase erythrocyte EPA þ DHA
composition to levels 4% [63].patients with MDD [80,139]. While this evidence suggests that
MDD may be associated with DHA deﬁcits selective to prefrontal
regions, in view of the limitations associated with the postmortem
approach these ﬁndings should be viewed as preliminary [134].
3.3. LCn-3 fatty acid supplementation studies
To date numerous small open-label or placebo-controlled
studies have investigated the antidepressant effects of short-term
LCn-3 fatty acid supplementation. Despite heterogeneity in study
design in terms of daily dose, LCn-3 fatty acid intervention,
EPA:DHA ratio, trial duration, concomitant medications, use of a
bioactive placebo (i.e., olive oil), and baseline symptom severity,
meta-analyses of controlled trials observed a signiﬁcant, albeit
modest, advantage of LCn-3 fatty acids over placebo for reducing
depression symptom severity in patients with MDD [10,77,143] or
bipolar disorder [165]. Additional data suggests that interventions
with a higher EPA to DHA ratio may have greater antidepressant
efﬁcacy [175]. Controlled and open-label trials have also found that
LCn-3 fatty acid supplementation, administered either adjunctively
or as monotherapy, signiﬁcantly reduces depression symptom
severity in pediatric and adolescent patients [40,138,146,188].
Controlled and open-label trials have also observed greater re-
ductions in depressive symptoms by combining LCn-3 fatty acids
with SSRI medications [67,99,138,155]. While this body of evidence
suggests that dietary LCn-3 fatty acid supplementation may have
acute ‘antidepressant’ effects, large-scale trials are warranted to
conﬁrm these ﬁndings.
In addition to acute antidepressant effects, emerging clinical
evidence suggests that higher LCn-3 fatty acid status may be pro-
tective against the initial development of MDD. A prospective sur-
veillance study found that lower baseline DHA levels were a
signiﬁcant predictor of depression development in human hepatitis
C patients during treatment with the pro-inﬂammatory cytokine
interferon-a (IFN-a) [172]. A second prospective surveillance study
found that lower baseline DHA levels, or a higher baseline AA/
EPA þ DHA ratio, were signiﬁcant predictors of depression devel-
opment in initially non-depressed human hepatitis C patients
during IFN-a treatment [120]. It is notable that a higher baseline
AA/EPA þ DHA ratio was also associated with greater increases in
the pro-inﬂammatory cytokine interleukin-6 (IL-6) during IFN-a
treatment [120]. A controlled supplementation trial found that
pretreatment with EPA alone, which increased both erythrocyte
EPA and DHA levels, but not DHA alone decreased the incidence of
depression during IFN-a treatment in hepatitis C patients [173]. In
view of evidence that MDD patients exhibit elevated indices of
peripheral [53] and central [168] inﬂammation, and LCn-3 fatty
acids and their bioactive metabolites have anti-inﬂammatory and
inﬂammation-resolving properties [47,76,167], these prospective
ﬁndings may have broader implications for understanding the role
of low LCn-3 fatty acid biostatus and pro-inﬂammatory signaling
cascades in the pathoetiology of MDD.
4. Neuroimaging studies
The initial onset of MDD frequently occurs during adolescence
[105], a developmental period associated with a sharp increase in
frontal cortex DHA levels [33] and rapid and dynamic changes in
frontal cortex functional and structural connectivity with limbic
structures that regulate mood [68,69,154]. Youth and adults with
MDD exhibit decreased frontal white matter integrity and reduced
connectivity within frontal lobe cortical networks [44,52,87]. It is
relevant, therefore, that recent neuroimaging studies found that
perinatal n-3 fatty acid deﬁciency in monkeys [72] or low eryth-
rocyte DHA biostatus in typically developing children [6] are
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cortical networks. Moreover, a recent intervention study found that
ﬁsh oil supplementation increased white matter microstructural
integrity in MDD patients in association with reductions in
depression symptom severity [37]. Furthermore, hippocampal gray
matter volume deﬁcits are among the most consistent and robust
neurostructural abnormality observed in MDD [102], and greater
habitual dietary LCn-3 fatty acid intake [42] and erythrocyte
EPA þ DHA composition [159] are associated with larger hippo-
campal volumes among healthy adults. It is also notable that higher
blood IL-6 levels were associated with smaller hippocampal gray
matter volume among healthy adults [123], and decreased corti-
costriatal functional connectivity in MDD patients [62]. While
additional research is required, these preliminary neuroimaging
ﬁndings suggest that low EPA þ DHA biostatus and associated in-
creases in pro-inﬂammatory signaling may be linked with abnor-
malities in cortical structure and function implicated in MDD.
5. Rodent studies
Animal studies have provided critical insight into the role of
dietary LCn-3 fatty acids in normal brain development. The
advantage of animal feeding studies is the ability to systematically
and selectively control n-3 fatty acid intake during development,
and perform invasive investigations of brain neurochemistry,
neuroanatomy, and/or gene expression. In general, feeding studies
have demonstrated that brain DHA accrual during perinatal
development is required for normal cortical neurogenesis
[20,46,100], neuroblast migration [190], neuronal differentiation
and arborization [30], neurotrophic factor expression [95,162],
nerve growth factor-induced neurite outgrowth and synapto-
genesis [31,96], and synaptic pruning [49]. Additionally, LCn-3 fatty
acids deﬁciency during development is associated with systemic
inﬂammation [121,133], and increased vulnerability to neurode-
generative processes associated with inﬂammation [151] and lipid
peroxidation [73,189]. These and other data suggest that there are
optimal LCn-3 fatty acids levels required for normal brain matu-
ration and resilience.
Additional evidence from animal studies suggests that deﬁcits in
dietary LCn-3 fatty acids during perinatal brain development
signiﬁcantly impacts neurotransmitter systems implicated in MDD
including serotonin (5-hydroxytryptamine, 5-HT) and dopamine.
Maternal dietary ﬁsh oil fortiﬁcation signiﬁcantly increases sero-
tonin concentrations in the frontal cortex [35] and attenuates re-
ductions in frontal cortex serotonin content in response to chronic
stress [183] in young adulthood. Conversely, perinatal deﬁcits in
cortical DHA accrual are associated with impaired fenﬂuramine-
induced elevations in serotonin release which are reversible with
early (P0eP14), but not later (P21), postnatal n-3 fatty acid sup-
plementation [108]. Perinatal deﬁcits in cortical DHA accrual are
also associated with reductions in midbrain expression of trypto-
phan hydroxylase-2, the rate-limiting enzyme in serotonin
biosynthesis [132], and elevations in 5-HT2A receptor binding
density in the rat frontal cortex [50]. The 5-HIAA/5-HT ratio, an
index of serotonin turnover, is signiﬁcantly elevated in the regional
brain of adult rats fed n-3-deﬁcient diets, and this increase was
positively correlatedwith plasma IL-6 levels and prevented by early
normalization of n-3 fatty acid status [133]. Importantly, the in-
crease in the 5-HIAA/5-HT ratio observed in the perinatal DHA-
deﬁcient rat brain is opposite to that produced by the SSRI anti-
depressant ﬂuoxetine [137]. Together this evidence suggests that
LCn-3 fatty acid status during development has an enduring impact
on central serotonin neurotransmission in young adult rats.
Consistent with clinical evidence implicating a dysregulation in
serotonin neurotransmission in the pathophysiology of depressionand aggression [11,41], post-weaning deﬁcits in cortical DHA
accrual are associated with elevated behavioral indices of depres-
sion and aggression in rats [51]. Importantly, dietary ﬁsh oil forti-
ﬁcation signiﬁcantly decreases depression-like behavior similar to
SSRI medications in the forced swimming test, an effect that may be
mediated by changes in 5-HT1A receptor function [32,94,184].
Combining dietary ﬁsh oil supplementation with ﬂuoxetine is
signiﬁcantly more effective than ﬂuoxetine alone for reducing
depression-like behavior in the forced swim test [111,112].
Although post-weaning deﬁcits in cortical DHA accrual are not
associatedwith diminished SSRI efﬁcacy in female rats in the forced
swim test [137], it is associated with abnormal behavioral activa-
tion in male rats [1]. It is also relevant that the Flinders Sensitive
Line rats, an inbred rat model of depression, exhibit constitutive
increases in regional brain AA/DHA ratio [74]. Together these
ﬁndings suggest that DHA biostatus is associated with serotonin-
regulated behaviors including depression and aggression, and
that ﬁsh oil supplementation has antidepressant-like effects similar
to SSRI medications.
A deﬁcit in mesolimbic dopamine neurotransmission has been
implicated in anhedonia, a core feature of depression [147,170]. Rat
studies have demonstrated that deﬁcits in brain DHA accrual dur-
ing perinatal development are associated with a signiﬁcant loss of
dopamine neurons in the ventral tegmental area, the source of
mesolimbic and mesocortical dopamine projections [3]. Perinatal
deﬁcits in brain DHA accrual is associated with enduring deﬁcits in
mesocortical and mesolimbic dopamine neurotransmission in
young adult rats that are reversible with early (P0eP14), but not
later (P21), postnatal n-3 fatty acid supplementation [107];
[193,194]. Adolescent rats subjected to perinatal deﬁcits in brain
DHA accrual also exhibit increased expression of tyrosine hydrox-
ylase, the rate limiting enzyme in dopamine biosynthesis, in the
dorsal striatum [23]. Maternal dietary ﬁsh oil supplementation
throughout gestation and lactation signiﬁcantly increases dopa-
mine concentrations in the frontal cortex of adult offspring [35].
These ﬁndings suggest that early perinatal brain DHA accrual is
critical for the functional maturation of mesocortical and meso-
limbic dopamine systems.
6. Future directions e clinical implementation
Together the reviewed body of translational evidence strongly
suggests that LCn-3 fatty acid deﬁciency, particularly during peri-
natal development, may represent a plausible and modiﬁable risk
factor for MDD. Among the clinical ﬁndings, meta-analyses of in-
dependent case-control studies demonstrate that MDD patients
exhibit signiﬁcantly lower blood EPA and/or DHA levels, which are
correlated with ﬁsh or ﬁsh oil intake, compared with demograph-
ically similar healthy controls. Additionally, cross-sectional evi-
dence and meta-analyses of controlled ﬁsh oil intervention studies
suggest that increasing EPA þ DHA biostatus mitigates risk for
depressive symptoms, and potentially suicidality and cardiovas-
cular disease. Therefore, translating this evidence into clinical
practice by implementing routine screening and treatment of low
blood EPA þ DHA levels in patients with MDD represents an
important future direction. Below we brieﬂy discuss existing re-
sources and general guidelines required for routine screening and
treatment of low blood EPA þ DHA levels in clinical practice.
7. Screening for LCn-3 fatty acid deﬁciency
There are currently several laboratory facilities that routinely
perform blood fatty acid analyses by gas-liquid chromatography.
For example, OmegaQuant, LLC is a Clinical Laboratory Improve-
ment Amendments (CLIA)-certiﬁed lab that specializes in
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com). For this procedure, whole blood (~25 uL) is obtained from a
ﬁnger prick and is spotted and dried onto anti-oxidant treated card
which is then shipped at ambient temperature. Analogous to
routine cholesterol testing, this approach can provide a valid, reli-
able, and relatively non-invasive measure of a patient's EPA þ DHA
biostatus. Erythrocyte EPA þ DHA composition (‘omega-3 index’)
has been widely characterized as a risk biomarker in the context of
coronary heart disease [84]. Based in part on prospective longitu-
dinal evidence, erythrocyte EPA þ DHA composition of 4% of total
fatty acid composition is thought to place one at ‘high risk’ for
sudden cardiac death, whereas>8% is protective [82]. BecauseMDD
is associatedwith excess prematuremortality attributable in part to
cardiovascular-related diseases [9,152], and the erythrocyte
EPAþ DHA deﬁcits consistently observed in MDD patients [118] are
similar to patients suffering acute coronary syndrome [22](Fig. 1),
the same risk categories may be appropriate within the context of
clinical practice. It is also notable that erythrocyte EPA þ DHA
composition of 4% is highly prevalent in youth with MDD, and
may therefore aid in the identiﬁcation of youth that may be at
elevated risk for developing MDD. For example, our study found
that 90% of adolescents with SSRI-resistant MDD exhibited eryth-
rocyte EPA þ DHA composition of 4% [138]. Collectively, these
data support the idea that erythrocyte or whole blood EPA þ DHA
composition of 4% can be considered to be a ‘state of deﬁciency’
that requires corrective intervention.
8. Treating LCn-3 fatty acid deﬁciency
The U.S. Food and Drug Administration (FDA) considers LCn-3
fatty acid doses up to 3 g/d to be ‘generally regarded as safe’, and
the European Food Safety Authority (EFSA) considers doses up to
5 g/d to be safe. The American Psychiatric Association has adopted
the consensus recommendations of the American Heart Association
for an EPA þ DHA dose of 1 g/d in patients with MDD [65]. The
American Heart Association also recommends 3 g/d EPA þ DHA for
reducing elevated triglyceride levels. Prescription ethyl ester
EPA þ DHA (Lovaza® in the US, Omacor® in Europe, GlaxoSmithK-
line), puriﬁed ethyl ester EPA containing no DHA (Vascepa®, Amarin
Corporation), and a free versus ethyl ester EPA þ DHA formulation
(Epanova®, AstraZeneca) have been approved by the U.S. FDA for
the treatment of hypertriglyceridemia (500 mg/dL). More
recently a generic version of Lovaza has become available (Teva
Pharmaceuticals USA, Inc.). Over-the-counter ﬁsh oil supplements
containing similar ethyl ester EPA þ DHA concentrations are also
widely available. It is important to note, however, that no LCn-3
fatty acid formulation is currently approved by the FDA for the
treatment of any psychiatric disorder, and reimbursement for off-
label use is ultimately at the discretion of the insurance provider.
Controlled intervention studies suggest that daily EPA þ DHA
doses of 1e2 g are sufﬁcient to increase erythrocyte EPA þ DHA
composition to levels 4% [63]. EPA þ DHA doses in the range of
1e4 g/d in a 2:1 EPA to DHA ratio are efﬁcacious for the treatment of
depressive symptoms [77,175]. Lower initial starting doses may be
appropriate for children. For example, a daily dose of 600mg ﬁsh oil
monotherapy signiﬁcantly reduced depression symptom severity
in children with MDD [146]. As with other psychotropic medica-
tions, upward dose titration may be required as clinically indicated.
For example, in an open-label ﬂexible dosing study LCn-3 fatty acid
monotherapy led to a statistically signiﬁcant reduction in depres-
sion (and manic) symptom severity scores in pediatric bipolar pa-
tients [188]. In this study the starting dose was 1.3 g/d of
EPAþDHA, themaximumdosewas 4.3 g/d, and themean dosewas
2.6 g/d. While there is a need for additional dose-titrating sec-
ondary prevention trials to elucidate optimal LCn-3 fatty aciddosing strategies, existing evidence suggests that a 1 g/d starting
dose of EPA þ DHA is safe and well-tolerated in pediatric, adoles-
cent, and adult psychiatric patients.
Fish oil and LCn-3 fatty acids have an established long-term
safety record in the general population. Potential adverse events
associated with LCn-3 fatty acid supplementation include gastro-
intestinal disturbances, including nausea, diarrhea, gastroesopha-
geal reﬂux, eructation, and less commonly emesis. In double-blind
clinical trials of adult patients, the principal adverse events re-
ported after chronic (8e12 weeks) treatment were gastrointestinal
problems, and were considered mild and reported as frequently in
patients receiving the placebo [65]. In studies conducted in pedi-
atric and adolescent patients, no clinically-signiﬁcant treatment-
emergent adverse events were reported at doses up to 4.3 g/
d [40,146,188]. In adults, treatmentwith LCn-3 fatty acid doses up to
7.5 g/d for 6 months were found to be well-tolerated [191]. To
minimize the gastrointestinal adverse events associated with LCn-3
fatty acids, patients should be instructed to take their capsules with
meals. Although taking ﬁsh oil at high doses (>3 g/d) has been
associated in isolated cases with increased bleeding time in sub-
jects also taking anticoagulant medications [28], controlled clinical
trials have found that chronic high dose EPA þ DHA alone or in
combination with aspirin does not increase risk for clinically-
signiﬁcant increases in bleeding time [59,83,144]. Another safety
consideration involves the potential threat of contamination of ﬁsh
and seafood with methyl mercury, PCBs, and other environmental
pollutants. However, most over-the-counter ﬁsh oil supplements
are highly puriﬁed and cannot exceed U.S. FDA limits for PCBs. As
with all medications, patients should be informed of potential risks
associated with LCn-3 fatty acids, and patients with an allergy to
shellﬁsh or seafood should be closely monitored.
9. Conclusions
Major advances in the treatment and prevention of MDD will be
accelerated by the identiﬁcation of modiﬁable pathogenic factors
conferring vulnerability. Evidence emerging over the past three
decades suggests that habitual dietary LCn-3 fatty acid insufﬁ-
ciency, particularly during perinatal development, may represent a
modiﬁable risk factor for MDD. Cross-sectional fatty acid compo-
sition studies provide strong evidence that adolescent and adult
patients withMDD exhibit signiﬁcant blood LCn-3 fatty acid deﬁcits
compared with healthy controls. Dietary supplementationwith ﬁsh
oil is sufﬁcient to correct blood LCn-3 fatty acid deﬁcits in MDD
patients, and controlled trials suggest that LCn-3 fatty acid sup-
plementation may reduce depressive symptoms in MDD patients.
While controversial, evidence also suggests that LCn-3 fatty acid
deﬁciency may increase risk for suicide and cardiovascular disease,
two principle causes of excess premature mortality in patients with
MDD. Recent prospective evidence further suggests that higher
peripheral LCn-3 fatty acid status is protective against the initial
development ofMDD in response to inﬂammation, and suggest that
low LCn-3 fatty acid biostatus may increase risk for depressive
symptoms by augmenting pro-inﬂammatory responsivity. Addi-
tionally, neuroimaging and rodent neurodevelopmental studies
provide evidence that LCn-3 fatty acid insufﬁciency impacts brain
development in a manner relevant to the pathophysiology and
treatment of MDD. When taken collectively, these translational
ﬁndings provide a strong empirical foundation in support of dietary
LCn-3 fatty acid deﬁciency being a modiﬁable risk factor for MDD.
While this body of evidence provides a compelling rationale to
screen and treat LCn-3 fatty acid deﬁciency in patients with MDD, it
has been slow impact conventional psychiatric training and prac-
tice. This may be due in part to a general lack of nutritional training
in psychiatry, though the ﬁeld is slowing evolving and nutritional
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meta-analysis have found that LCn-3 fatty acids are efﬁcacious for
reducing depression symptom severity antidepressant, it is
important to recognize that neurostructural and neurochemical
perturbations resulting from LCn-3 fatty acid deﬁciency during
development may not be reversible with short-term treatment.
This is directly supported by rodent studies ﬁnding that enduring
impairments in serotonin and dopamine neurotransmission
resulting from perinatal n-3 fatty acid deﬁciency are reversible with
early but not later n-3 fatty acid supplementation despite
normalization of LCn-3 fatty acid biostatus. Therefore, early
detection and treatment of LCn-3 fatty acid deﬁciency may be
required to exert maximal protection against the initial develop-
ment of MDD. Indeed, because LCn-3 fatty acidmonotherapy is safe
and well-tolerated it is ideally suited as a prodromal intervention
for youth at increased risk for developing MDD. This approach is
supported by the observation that ﬁsh oil supplementation pre-
vented or delayed the onset of psychosis in ultra-high risk youth
[7,8]. Additionally, within a ‘clinical staging’ framework LCn-3 fatty
acidmonotherapywould also represent a safe ﬁrst-line intervention
in youth with MDD, particularly those at risk for SSRI-associated
adverse events.
While there is a need for additional research to optimize and
standardize LCn-3 fatty acid screening and treatment approaches,
current evidence and existing infrastructure support widespread
implementation in psychiatric practice. As proof-of-concept, our
group recently initiated a pilot program that routinely performs
blood fatty acid testing in all patients admitted to an in-patient
psychiatric clinic in suburban Cincinnati [142]. To date we have
performed whole blood fatty acid tests on over one hundred pa-
tients with different psychiatric disorders, including MDD.
Consistent with prior cross-sectional studies, initial results suggest
that the majority of patients exhibit whole blood EPA þ DHA levels
at 4. In several notable cases, treating EPA þ DHA deﬁciency with
either prescription or over-the-counter ﬁsh oil supplements
resulted in remarkable and sustained improvements in mood
symptoms. Although these data must be viewed as preliminary,
they demonstrate the feasibility of implementing routine screening
and treatment of EPA þ DHA deﬁciency in psychiatric practice.
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